Vizual Stocks works best vertically on mobile.
VizualStocks APIOperating KPI and segment definitions available for Jazz Pharmaceuticals (JAZZ) through the VizualStocks API.
Jazz net product sales of the cannabidiol medicine sold as Epidiolex and Epidyolex for rare epilepsies. The combined line includes the product across its regional brand names.
epidiolexRevenueJazz net product sales of Modeyso, the dordaviprone oncology medicine acquired with Chimerix in 2025. Reported history includes recognized pre-launch access revenue when explicitly included by the issuer.
modeysoRevenueJazz royalty revenue from licensed high-sodium oxybate authorized generic sales. This is separate from Jazz own net product sales of Xywav and Xyrem.
oxybateAGRoyaltyRevenueJazz net product sales of the asparaginase medicine sold as Rylaze and Enrylaze for acute lymphoblastic leukemia and lymphoblastic lymphoma. The line combines the regional brand names.
rylazeRevenueJazz net product sales of Xywav, its low-sodium oxybate oral medicine for narcolepsy and idiopathic hypersomnia. It excludes Xyrem branded sales and royalties from high-sodium authorized generics.
xywavRevenueJazz net product sales of Zepzelca, its lurbinectedin oncology medicine for small cell lung cancer. This measures recognized product revenue rather than trial milestones or royalty income.
zepzelcaRevenueJazz net product sales of Ziihera, its zanidatamab antibody therapy launched for HER2-positive biliary tract cancer. Pipeline indications and milestone payments are not product sales.
ziiheraRevenue